Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.

Our vision is a future where all refugees are included in the communities that host them, and where refugees can find meaningful employment. We look forward to a future where refugees are not only ...

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and ...

Aligned with Duke Engineering’s Character Forward initiative, Professor Siobhan Oca’s Ethics in Robotics and Automation course (ME 490) challenges students to see beyond technical skills and practice ...